6 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 6 separate news trends connected to Ionis, spanning July 9, 2026 through September 5, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 39 article observations and 37 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
Novartis' experimental heart drug Pelacarsen has failed a pivotal study, disappointing investors and cardiologists.
AstraZeneca and Ionis' failed heart disease trial raises questions about the future of RNA drugs
AstraZeneca's failed heart disease drug trial casts doubt on a promising class of treatments
Arrowhead Pharmaceuticals shares surged after Phase 3 trial success for its triglyceride-lowering drug, impacting competitor Ionis.
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.